TY - JOUR
T1 - Dispatch and delivery at the ER–Golgi interface
T2 - how endothelial cells tune their hemostatic response
AU - Kat, Marije
AU - Margadant, Coert
AU - Voorberg, Jan
AU - Bierings, Ruben
N1 - Funding Information: Work in our laboratory was funded by grants from the Landsteiner Stichting voor Bloedtransfusie Research (LSBR‐1707 and LSBR‐2005) and the Dutch Thrombosis Foundation (TSN 2017‐01). Publisher Copyright: © 2022 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
PY - 2022/11
Y1 - 2022/11
N2 - Von Willebrand factor (VWF) is a glycoprotein that is secreted into the circulation and controls bleeding by promoting adhesion and aggregation of blood platelets at sites of vascular injury. Substantial inter-individual variation in VWF plasma levels exists among the healthy population. Prior to secretion, VWF polymers are assembled and condensed into helical tubules, which are packaged into Weibel-Palade bodies (WPBs), a highly specialized post-Golgi storage compartment in vascular endothelial cells. In the inherited bleeding disorder Von Willebrand disease (VWD), mutations in the VWF gene can cause qualitative or quantitative defects, limiting protein function, secretion, or plasma survival. However, pathogenic VWF mutations cannot be found in all VWD cases. Although an increasing number of genetic modifiers have been identified, even more rare genetic variants that impact VWF plasma levels likely remain to be discovered. Here, we summarize recent evidence that modulation of the early secretory pathway has great impact on the biogenesis and release of WPBs. Based on these findings, we propose that rare, as yet unidentified quantitative trait loci influencing intracellular VWF transport contribute to highly variable VWF levels in the population. These may underlie the thrombotic complications linked to high VWF levels, as well as the bleeding tendency in individuals with low VWF levels.
AB - Von Willebrand factor (VWF) is a glycoprotein that is secreted into the circulation and controls bleeding by promoting adhesion and aggregation of blood platelets at sites of vascular injury. Substantial inter-individual variation in VWF plasma levels exists among the healthy population. Prior to secretion, VWF polymers are assembled and condensed into helical tubules, which are packaged into Weibel-Palade bodies (WPBs), a highly specialized post-Golgi storage compartment in vascular endothelial cells. In the inherited bleeding disorder Von Willebrand disease (VWD), mutations in the VWF gene can cause qualitative or quantitative defects, limiting protein function, secretion, or plasma survival. However, pathogenic VWF mutations cannot be found in all VWD cases. Although an increasing number of genetic modifiers have been identified, even more rare genetic variants that impact VWF plasma levels likely remain to be discovered. Here, we summarize recent evidence that modulation of the early secretory pathway has great impact on the biogenesis and release of WPBs. Based on these findings, we propose that rare, as yet unidentified quantitative trait loci influencing intracellular VWF transport contribute to highly variable VWF levels in the population. These may underlie the thrombotic complications linked to high VWF levels, as well as the bleeding tendency in individuals with low VWF levels.
KW - GBF1
KW - Golgi
KW - SEC22B
KW - SNARE
KW - STX5
KW - Von Willebrand disease
KW - Von Willebrand factor
KW - Weibel-Palade body
KW - endoplasmic reticulum
KW - endothelial cell
UR - http://www.scopus.com/inward/record.url?scp=85126020865&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/febs.16421
DO - https://doi.org/10.1111/febs.16421
M3 - Comment/Letter to the editor
C2 - 35246944
SN - 1742-464X
VL - 289
SP - 6863
EP - 6870
JO - FEBS journal
JF - FEBS journal
IS - 22
ER -